Drug intelligence / Profile preview

MK-4646

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-4646 is an investigational drug being evaluated for its potential to reduce HIV-1 viral load in humans. As of mid-2025, it is undergoing clinical trials to assess whether at least one dose level of the compound can meaningfully lower HIV-1 viral load in the blood. Detailed information regarding its mechanism of action, drug class, chemical structure, or specific molecular target has not been publicly disclosed. The primary indication currently under investigation is HIV-1 infection, and there is no available evidence of other diseases in development or approved indications[3][5][6][7][10].

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on MK-4646.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-4646.

Explore the full profile